-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 12, Liu Wenxian's group published a research paper entitled Myc inhibition tips the immune balance to promote antitumor immunity in the immunology journal "Cellular & Molecular Immunology.
Myc, as the most famous proto-oncogene, has always been the focus of researc.
After treating tumor-bearing mice with Myc inhibitor Mycro3, researchers found that regulatory T cells (Treg) in the tumor microenvironment were significantly decreased, CD8 + T cells were significantly increased, and tumor growth was slo.
This study focused on the function of the proto-oncogene Myc in anti-tumor immune responses, and demonstrated for the first time that the sensitivity of different T cell subsets to Myc inhibitors in the tumor microenvironment is determined by the expression of Myc protei.
Doctoral students Yang Chao and Liu Yun from the School of Life Sciences of Xiamen University and Hu Yudi, a master student from the School of Medicine, are the co-first authors of the pape.
Full text link: https://do.
(Photo/Wen Liu Wenxian's research group)